Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy.

Cellular oncology (Dordrecht, Netherlands) - 1 Dec 2022

Viol Fabrice, Sipos Bence, Fahl Martina, Clauditz Till S, Amin Tania, Kriegs Malte, Nieser Maike, Izbicki Jakob R, Huber Samuel, Lohse Ansgar W, Schrader Jörg

Abstract excerpt

PURPOSE: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) form a rare and remarkably heterogeneous group of tumors. Therefore, establishing personalized therapies is eminently challenging. To achieve progress in preclinical drug development, there is an urgent need for relevant tumor models. METHODS: We successfully established three gastroenteropancreatic neuroendocrine tumor (GEP-NET) cell lines...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Feasibility Studies
Share to ARID1A gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATR gene

Share to Intestinal Neoplasms

Share to Mutation

Share to Neuroendocrine Tumors

Share to Pancreatic Neoplasms

Share to Stomach Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 36269546
DOI: 10.1007/s13402-022-00727-z
PMCID: PMC9747820

Genes

DAXX
ARID1A
ATR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy.PMID 36269546Read ↗

Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted TherapySemantic proximity Read ↗

Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review.Semantic proximity Read ↗

Evaluation of therapeutic agent selection based on comprehensive genomic profiling in gastroenteropancreatic neuroendocrine neoplasmsSemantic proximity Read ↗

The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.Semantic proximity Read ↗

The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumoursSemantic proximity Read ↗

Molecular Classification of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms: Are We Ready for That?Semantic proximity Read ↗

Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine NeoplasmsSemantic proximity Read ↗

An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping.Semantic proximity Read ↗

Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and modelsSemantic proximity Read ↗

Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the FutureSemantic proximity Read ↗

Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma.Semantic proximity Read ↗

Preclinical Models of Neuroendocrine NeoplasiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.